BACKGROUND AND PURPOSE: Diagnostic confidence in motor neuron disease may be improved by the use of advanced MR imaging techniques. Our aim was to assess the accuracy (sensitivity/specificity) and agreement of combined 1 H-MR spectroscopy (proton MR spectroscopy) and diffusion tensor imaging (DTI) at 3T in patients with suspected motor neuron disease regarding detection of upper motor neuron (UMN) dysfunction.
A myotrophic lateral sclerosis (ALS), Lou Gehrig syndrome or Charcot disease, is the most common progressive motor neuron disease. 1 Classic ALS affects the upper (UMN) and lower motor neurons (LMN), but cases with predominant UMN or LMN involvement also occur. It is still debated whether primary lateral sclerosis (PLS) and ALS are distinct disorders or manifestations of a single disorder, and a classification into ALS, UMN-dominant ALS, and PLS has been proposed to systematize future trials, 2 hence the correctness of UMN assessment is crucial.
In addition to traditional diagnostic steps, such as electromyography, transcranial magnetic stimulation, 3, 4 and assessment according to established clinical rating scales (eg, ElEscorial [EE] 5 or ALS Functional Rating Scale-Revised [ALSFRS-R 6 ]), recent promising attempts to improve diagnostic confidence of UMN assessment used advanced MR imaging techniques: 1 H-MR spectroscopy (proton MR spectroscopy), [7] [8] [9] [10] [11] diffusion tensor imaging (DTI), [12] [13] [14] [15] [16] [17] [18] [19] diffusion tensor tractography (DTT), 20 or combinations thereof. 21, 22 However, systematic evaluation of their concordance in the same patients is still rare. 21, 23 To obtain a definite diagnosis early in the disease is important for therapeutic intervention, 21, 24 quality of life, 17, 25, 26 and monitoring therapeutic trials. 16, 22 Cervical myelopathy, Kennedy syndrome (spinobulbar muscle atrophy, [SBMA] ), peripheral nerve lesions, and multifocal polyneuropathy are, among others, differential diagnoses that have to be excluded. The clinical diagnosis is especially difficult when UMN involvement remains unclear. The previously mentioned techniques not only hold the promise of a more specific and potentially objective MR imaging measure but may even lead to a biomarker of disease severity. In contrast, most characteristics observed on structural MR imaging, such as corticospinal tract (CST) hyperintensities in T2-weighted, proton density, and fluid-attenuated inversion recovery (FLAIR) imaging [27] [28] [29] [30] [31] [32] ; hypointense precentral gyrus changes 33, 34 ; or marked frontal or callosal atrophy, 35 are rather uncertain. 31, 32 CST hyperintensities are frequently found in healthy individuals, whereas the hypointense precentral gyrus sign apparently is motor neuron disease-specific according to Ishikawa et al 33 but occurs only in a minority of patients with ALS. To our knowledge, none of these signs have yet been studied at 3T. The principal aim of the present study was to evaluate the diagnostic accuracy of combined MR spectroscopy and DTI at 3T as an additional diagnostic tool in patients with suggested motor neuron disease and to provide an estimate of their concordance when applied to the same patients.
Materials and Methods

Healthy Controls and Patients
Study participants comprised 2 separate groups of healthy controls (20 for MR spectroscopy: 13 men; mean age, 51 years; range, 30 -74 years; 34 for DTI: 17 men; mean age, 53 years; range, 33-79 years) and 18 patients with suggested motor neuron disease (11 men; mean age, 59 years; range, 45-73 years). The control samples were acquired independently in preceding investigations by using the same MR imaging equipment and techniques as in the actual patient study. The overall group of patients consisted of patients admitted consecutively to our Neuromuscular Clinic for suspected motor neuron disease. Mean disease duration (symptom onset to time of MR spectroscopy/ DTI) was 20 Ϯ 9 months. Neurologic rating was based on the EE and ALSFRS-R scales and was conducted by an experienced neurologist (U.W.). On rigorous examination, patients were grouped according to the EE scale; ALSFRS-R served to further assess disease severity. Group I was composed of the healthy controls; group II comprised 4 patients who did not meet EE criteria; group III, 7 individuals with "clinically possible" assessments; and group IV, 7 patients with clinical evidence for UMN involvement (4 "definite" and 3 "clinically probable" patients). No patients with familial ALS were included in this study.
MR Imaging
All of the MR imaging data were acquired on a 3T Achieva MR imaging system (Philips Medical Systems, Best, the Netherlands). Routine imaging pulse sequences included axial T2-weighted turbo spin-echo (TSE) scans (TR, 4000 ms; TE, 80 ms, TSE factor, 15; section thickness, 5 mm), isotropic FLAIR imaging (TR, 12000 ms; TE, 140 ms, TSE factor, 40; section thickness, 2 mm; section gap, 0 mm; voxel dimensions, 2 ϫ 2 ϫ 2 mm 3 ), and additional coronal T2-weighted planscans (TR, 4752 ms; TE, 80 ms; section thickness, 4 mm) for targeting the spectroscopic voxel (volume of interest [VOI] ). The geometry of the FLAIR sequences was identical to the DTI dataset parameters detailed below; DTI/FLAIR overlays were used as an anatomic reference frame for a guided placement of tracking seeds during tractography. Furthermore, 2 observers independently read all anatomic images regarding occurrence of 1) CST hyperintensities on FLAIR images, and 2) the hypointense precentral gyrus sign in T2-weighted and/or FLAIR sequences.
MR Spectroscopy
For MR spectroscopy, bilateral 30 ϫ 25 ϫ 20 mm 3 VOIs were placed anterior to the central sulcus ( Fig 1A) . VOI positioning was done semiautomatically by the manufacturer-supplied "SmartPlan" algorithm 36 Finally, absolute concentrations of choline (Cho) and phosphocreatine (PCr) and relative metabolite ratios NAA/Cho and NAA/PCr were calculated from the H 2 O-suppressed acquisition with TE 140 ms, with the concentrations corrected for partial CSF volume referring to brain tissue contents within the VOI (thus not being influenced by higher CSF volume in the VOI due to brain atrophy). Total MR spectroscopy scanning time was 20 minutes for all acquisitions from both VOIs, including spectral preparations.
DTI
For DTI, a sensitivity encoding 40 [41] [42] [43] Seed regions were placed in the pons, posterior limb of the internal capsule, and the centrum semiovale. Line-propagation thresholds to terminate the tracking process were Յ0.15 for fractional anisotropy (FA) and Ն27°as an angle threshold, respectively. On the basis of the 3D CST tractographies, 2D FA overlay maps on which the corticospinal tract could be easily identified were generated throughout the whole brain (Fig 1B) , allowing a more unbiased determination of diffusion characteristics along the CSTs, as shown by Wang et al, 21 compared with manual unguided region-of-interest placement. Furthermore, the DTI atlas project by Wakana et al 44 was used as an additional anatomic framework. FA and mean diffusivity (MD) were measured bilaterally at the level of the pyramid, pons, cerebral peduncles, internal capsule, corona radiata, and precentral gyrus (Fig 1B) . The region-of-interest size was 4 ϫ 4 voxels, thus covering an area of 64 mm 2 in both hemispheres at every measurement level. Region-of-interest placement was done in noninterpolated images to minimize partial volume effects possibly induced by CSF and structures adjacent to the CST (such as the basal ganglia). Region-of-interest independent fiber tract analysis was performed in a volumetric approach that calculated the number of voxels of which CSTs were composed and their diffusion characteristics (FA, MD) along the whole fiber "object." Observers were blinded to results of clinical ratings. MR spectroscopy and DTI were evaluated independently by different investigators.
Follow-Up Examinations
The clinical course could be monitored in 6 equivocal cases (patients III/2-III/7, Table 1 ) and in 12 patients overall (IV/3-IV/6, III/1-III/7, II/2; Table 1 ). MR imaging follow-up examinations were performed in 3 patients without clear UMN signs with a mean interval of 168 days (III/4, III/6, II/2; Table 1 ).
Statistics
For statistical analyses, the mean values for the right and left hemispheres were calculated and used in the analysis. FA values were scaled by a factor of 1000. Nonparametric Mann-Whitney-Wilcoxon tests were used to check for equality of means between different subgroups. Single results for MR spectroscopy and DTI were assumed to be pathologic when they were below the double SDs of healthy controls (in 2 or more adjacent regions regarding the FA and MD measurements). For post hoc determination of combined MR spectroscopy/ DTI sensitivity and specificity, the clinical evidence for UMN involvement served as a ground truth on the basis of which the correctness of combined results was rated. An overall negative result was presumed in the case of divergent or negative findings in both techniques; reduction beyond the single SD threshold for MR spectroscopy and beyond the double SD threshold in only 1 region for DTI was regarded as a pathologic result of the MR spectroscopy/ DTI combination.
Results
Patients
The ALSFRS-R scores of the 18 patients declined over the subgroups: group II conformed more closely to the maximum score of 48 (ie, 36), whereas groups III and IV were nearly even at a score below 30 (ie, 28 and 29, respectively). The mean degree of impairment (ALSFRS-R) was 30 Ϯ 5. Group II (criteria not met) motor neuron disease differential diagnoses were cervical myelopathy (II/1, Table 1 ), polyneuropathy (II/2), SBMA (II/3), and suggested spinal muscle atrophy (II/4).
Structural 3T MR Imaging
Anatomic MR imaging signs as described previously (ie, concurrent/simultaneous occurrence of both the hypointense cortical band and CST signal-intensity changes) were present in 3 of the 7 group IV (EE "probable/definite") patients (IV/1, IV/4, IV/7) and in neither of the healthy controls. Overall, they were observed in a total of 5 patients (IV/1, IV/4, IV/7, III/7, II/1), with both signs present simultaneously in all except 1 patient who belonged to the clinically possible group and in whom CST signal intensity elevation was absent (III/7). Most interesting, both criteria were present in a patient with severe cervical myelopathy in whom motor neuron disease could be ruled out (II/1).
MR Spectroscopy
Metabolite ratios for NAA/Cho and NAA/PCr and absolute quantifications for these metabolites are detailed in Table 2 .
Normal ranges for NAA/Cho and NAA/PCr were 2.11 Ϯ 0.14 and 1.82 Ϯ 0.12, respectively. NAA/Cho was a robust parameter to enable proper differentiation of patient subgroups, showing a decline from patients who did not meet EE criteria (mean ratio, 2.10 Ϯ 0.25) toward the probable/definite group (1.72 Ϯ 0.20, P Ͻ .05, Fig 2A) . Both parameters were lowest in group IV (EE probable/definite).
DTI
Comparison of FA in the central region (Table 3 and Fig 2B) elucidates that group IV (EE and IV were significantly lower in the upper 3 regions of measurements (Table 3) , except for the mean precentral gyrus FA reduction of group III (which also was beyond the 1 SD threshold). In the brain stem regions, the groups resided closely together: There was only 1 larger FA difference in the pons region for group IV (P ϭ .062, Table 3 ). MD exhibited statistically significant differences with MD elevation in the internal capsule in group IV compared with healthy controls (849. 43 
Follow-Up Examinations
After 6 months, a clinical follow-up assessment was obtained in 12 patients: There was a progression from the clinically probable to EE "definite" state in 1 patient with positive initial DTI and MR spectroscopy results (IV/4, Table 1 ), whereas 3 patients of the clinically possible group still had no clinical or electrophysiologic evidence of the UMN being affected (III/2, III/5, III/7). Two clinically possible patients received a second MR spectroscopy/DTI analysis with newly marked FA reduction that had not been present in their initial studies. Compared with the initial state, the first patient (III/4) had a 35% relative FA reduction in the pons (which was the maximum of observed changes) and further reduction in the left and right centrum semiovale (below the 2 SD threshold). Correspondingly, this patient newly exhibited a positive Babinski sign and hyperreflexia. The second patient (III/6) had new FA decrease below the 2 SD threshold for 2 adjacent regions of measurement (the precentral gyrus and centrum semiovale), thus becoming "positive" regarding motor neuron disease-defining DTI criteria. Clinically, there was a progression of symptoms in this patient, with a lesion of the central pathways to the right leg in electrophysiology. No newly evolved symptoms could be observed in the other follow-up patients (IV/3, IV/5, IV/6, III/1, III/3, and II/2). Patient III/1 still lacked any LMN signs (thus representing a case of UMN-dominant ALS or PLS) at the time of his follow-up; patient II/2 received an MR imaging follow-up, with negative findings (as were the findings of his initial clinical and MR evaluation). (Table 3) . Note:-MWW indicates Mann-Whitney-Wilcoxon test; Cent. Semi., centrum semiovale; Precent. Gyr., precentral gyrus; DTI, diffusion tensor imaging; FA, fractional anisotropy. * The lowest mean FA in comparison with controls is found in the internal capsule, centrum semiovale, and the precentral gyrus of group IV (EE clinically probable/definite) and the internal capsule and centrum semiovale for patients of group III (EE clinically possible). The rightmost FA/MD CST columns illustrate diffusion characteristics averaged for the entire CST. FA ranges from 1000 (maximum anisotropy) to 0 (no anisotropy). MD exhibits statistically significant differences with elevation in the internal capsule in group IV compared with healthy controls (data not shown).
Synopsis
Clinical assessment, MR spectroscopy, and DTI findings are summarized in 
Discussion
Whereas anatomic 3T MR imaging signs are by far not sufficient, combined 3T MR spectroscopy and DTI improve diagnostic accuracy in the work-up of patients with suspected motor neuron disease: There was no false-negative case in patients with EE probable or definite assessments. This combination gave further evidence to exclude all patients with suspected motor neuron disease who did not meet EE criteria and to include 2 clinically possible patients (by means of follow-up examinations).
In the subset of patients who lacked UMN signs-which is the clinically most important group-markedly reduced mean FA was found in 3 regions (the internal capsule, the centrum semiovale, and the motor cortex). Progressing FA decline in this group was observed in 2 follow-up examinations. We thus provide data for a patient subgroup with clinical lower motor neuron disease only, which is considered a target group for future ALS studies. 21, 45 Because studies using high-field magnets (Ն3T) and applying both spectroscopy and DTI to the same patients with suspected ALS are still rare, 22 ,23 reviews regarding congruent or incongruent results of both techniques are essential. In the present study, MR spectroscopy and DTI agreement was high: Markedly reduced FA with corresponding NAA reductions occurred in all clinically definite/probable patients with ALS, with a total of only 3 divergent findings. Furthermore, so far FA measurements were confined to a limited number of CST levels only. 21 FA and MD data in our study were collected along the whole CST at levels of the brain stem, the internal capsule, the corona radiata, and the precentral gyrus and revealed changes in several adjacent regions that are complementary to abnormalities detected by the (centrally placed) spectroscopic VOI. We also calculated FA and MD statistics for the tracked CST as whole objects in all patients and controls. Most interesting, this approach yielded no larger FA or MD differences for the entire CST but showed a significant reduction of CST voxels toward the possible and definite groups, as has been indicated by volumetric analyses earlier. 46 It may well be that the results of fiber tracking algorithms in patients with motor neuron disease predominantly reveal unchanged CST remainders, which are consecutively composed of smaller amounts of voxels and throughout which diffusion characteristics are not significantly altered compared with healthy subjects. Macroscopic abnormalities in structural MR images predominantly occur in advanced stages of the disease. Thus, DTI-based CST volumetry or voxel-based morphometry 47 may be able to detect structural changes earlier than it would be possible by relying on visually recognizable anatomic MR imaging signs alone.
It has been a matter of debate whether MD elevation reflects more chronic changes in the disease process of ALS. In this study, significant MD elevation only was observed at the internal capsule for the clinically probable and definite patients. MD differences tend to be lost caudally in the CST 48 and, furthermore, could not be ascertained by other groups. 22 For the motor region and centrum semiovale, it is questionable whether MD changes correlate with disease processes or are not rather due to extracellular volume increases in the course of atrophic changes.
As shown in our previous ALS studies using MR spectroscopy, the NAA/Cho metabolite ratio served as a robust parameter with good discriminatory power for patient subgroups. 8, 9 Single-voxel spectroscopy in combination with DTI was used rather than spectroscopic imaging because of its inherent higher signal-intensity-to-noise ratio (96 averages were used as a maximum for our measurements) and the possibility for a reliable absolute quantification of metabolites. However, evaluation with MR spectroscopy alone is inferior to the MR spectroscopy/DTI combination, as is well illustrated by the pathologic MR spectroscopy findings in the patient with Kennedy syndrome (who had normal FA), which could have lead to the erroneous assumption of motor neuron disease (whereas there is a normal average life expectancy in the case of SBMA; pathologic MR spectroscopy findings in Kennedy disease have been reported earlier 49 ).
Conclusion
The MR spectroscopy/DTI combination at 3T effectively adds to the detection of motor neuron disease and improves diagnostic confidence.
